Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs TransMedics Group Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.58 (market cap $7.11B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 2.6× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 22,683,268). Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and TransMedics Group Inc for 24 Days on average.
| NCLH | TMDX | |
|---|---|---|
Market Cap | $7.11B | $2.74B |
Volume | 22,683,268 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $150.42 |
52-Week Low | $14.12 | $61.99 |
Typical Hold Time | 68 Days | 24 Days |
Enterprise Value | $21.93B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $15.57, up 3.46% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Revenue has grown from $4.8B in 2022 to $9.83B in 2025, though net income margin declined to 4.3% from 9.6% in 2024.
The outlook is mixed: analyst consensus is bullish with a $20.86 price target, but the company faces yield pressure and high debt levels. Investment opportunity lies in continued operational recovery and compelling valuation, while risks include Caribbean pricing pressure and significant leverage that could constrain financial flexibility.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
